二甲苯氧庚酸治疗患者脂蛋白升高:一个试点研究。

文章的细节

引用

复制到剪贴板

Fereshetian AG,戴维森M,哈伯H,黑色的DM

二甲苯氧庚酸治疗患者脂蛋白升高:一个试点研究。

中国药物Investig。1998; 16 (1): 1 - 7。doi: 10.2165 / 00044011-199816010-00001。

PubMed ID

18370512 (在PubMed

]

文摘

目的:本试验研究了高剂量的疗效二甲苯氧庚酸(2400毫克/天)升高患者脂蛋白(a) [Lp (a)]。Lp (a)已被证明是一个独立的危险因素对冠心病(CHD)的发展。病人:11个患者血清Lp (a) > / = 45 mg / dl参加了这个为期12周的研究。最初,所有患者接受口服二甲苯氧庚酸600毫克每日两次。每隔四周,增加了600毫克的剂量对患者能够容忍增加最多2400毫克/天。结果:8例完成了研究。三个病人符合预定的标准的临床意义的Lp (a)减少33%。Lp (a)的平均百分比变化并不显著值为-18.3 + / - 15.4% (p = 0.14, 1-tailed)。所有患者表现出显著降低血浆甘油三酯。均值变化百分比是-62.5 + / - 1.8% (p < 0.001, 1-tailed)。 The mean percentage change in total cholesterol was -12.4 +/- 3.8% (p = 0.007, 1-tailed). Gemfibrozil was considered suspect in five of 16 adverse events reported, but only one of these (dyspepsia) caused withdrawal from the study. For all patients participating in the study no adverse event was characterised as severe. CONCLUSION: While the small number of patients does not allow any definitive conclusion on effectiveness to be drawn, the results suggest that further randomised studies utilising larger patient numbers appear warranted.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

二甲苯氧庚酸